Literature DB >> 31590151

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

Shaji K Kumar1, Natalie S Callander2, Jens Hillengass3, Michaela Liedtke4, Muhamed Baljevic5, Erica Campagnaro6, Jorge J Castillo7, Jason C Chandler8, Robert F Cornell9, Caitlin Costello10, Yvonne Efebera11, Matthew Faiman12, Alfred Garfall13, Kelly Godby14, Leona Holmberg15, Myo Htut16, Carol Ann Huff17, Yubin Kang18, Ola Landgren19, Ehsan Malek12, Thomas Martin20, James Omel21, Noopur Raje22, Douglas Sborov23, Seema Singhal24, Keith Stockerl-Goldstein25, Carlyn Tan26, Donna Weber27, Alyse Johnson-Chilla28, Jennifer Keller28, Rashmi Kumar28.   

Abstract

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.

Entities:  

Year:  2019        PMID： 31590151     DOI： 10.6004/jnccn.2019.0049

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  31 in total

1.  Maintenance Therapy With Bortezomib and Dexamethasone for Transplant-ineligible Patients With Multiple Myeloma.

Authors:  Yurika Noguchi; Noriyoshi Iriyama; Hiromichi Takahashi; Yoshihito Uchino; Masaru Nakagawa; Takashi Hamada; Kazuhide Iizuka; Takashi Koike; Kazuya Kurihara; Toshihide Endo; Tsutomu Yoshida; Katsuhiro Miura; Tomohiro Nakayama; Yoshihiro Hatta; Masami Takei
Journal:  Cancer Diagn Progn       Date:  2021-05-03

2.  Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients.

Authors:  Qiaolin Zhou; Fang Xu; Jingjing Wen; Jing Yue; Ya Zhang; Jing Su; Yiping Liu
Journal:  Clin Exp Med       Date:  2022-09-12       Impact factor: 5.057

3.  Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma.

Authors:  Paul G Richardson; Sundar Jagannath; Ajai Chari; Dan T Vogl; Meletios A Dimopoulos; Philippe Moreau; David Dingli; Lee-Jen Wei; Joshua Richter; Noa Biran; David Siegel; William Reichmann; Lingling Li; Shijie Tang; Jean-Richard Saint-Martin; Anita Joshi; Michael Kauffman; Jatin Shah; Sharon Shacham; Sagar Lonial
Journal:  EJHaem       Date:  2020-11-25

4.  Bortezomib, epirubicin, and dexamethasone (PAD) results in superior free-progression survival compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment in non-transplantation newly diagnosed multiple myeloma patients aged between 50 to 65: a retrospective single-center analysis in non-transplant patients.

Authors:  Liang Chen; Ke Yi; Hongyan Lan; Yajun Zhang; Simin Jin; Xiaoyu Mou; Hongming Xian; Weijun Fu; Rong Li
Journal:  Ann Transl Med       Date:  2022-06

5.  Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients.

Authors:  Mengmeng Dong; Jinna Zhang; Xiaoyan Han; Jingsong He; Gaofeng Zheng; Zhen Cai
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

Review 6.  Advances in Management for Older Adults With Hematologic Malignancies.

Authors:  Ashley E Rosko; Raul Cordoba; Gregory Abel; Andrew Artz; Kah Poh Loh; Heidi D Klepin
Journal:  J Clin Oncol       Date:  2021-05-27       Impact factor: 50.717

7.  Roles of LINC01473 and CD74 in osteoblasts in multiple myeloma bone disease.

Authors:  Fengping Peng; Siyang Yan; Hui Liu; Zhaoyun Liu; Fengjuan Jiang; Panpan Cao; Rong Fu
Journal:  J Investig Med       Date:  2022-02-10       Impact factor: 3.235

8.  Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption.

Authors:  Phoebe K Mondala; Ashni A Vora; Tianyuan Zhou; Elisa Lazzari; Luisa Ladel; Xiaolin Luo; Youngsoo Kim; Caitlin Costello; A Robert MacLeod; Catriona H M Jamieson; Leslie A Crews
Journal:  Cell Stem Cell       Date:  2021-01-20       Impact factor: 24.633

9.  Correlations between apparent diffusion coefficient values of WB-DWI and clinical parameters in multiple myeloma.

Authors:  Bei Zhang; Bingyang Bian; Zhiwei Zhao; Fang Lin; Zining Zhu; Mingwu Lou
Journal:  BMC Med Imaging       Date:  2021-06-08       Impact factor: 1.930

10.  Chronic Diarrhea as the Presenting Feature of Amyloidosis with Multiple Myeloma: A Case Report Diagnosed by a Myocardial Biopsy.

Authors:  Shinsuke Otagiri; Sae Nakajima; Takehiko Katsurada; Kensuke Sakurai; Kana Yamanashi; Takahide Ara; Emi Takakuwa; Tomoko Mitsuhashi; Naoya Sakamoto
Journal:  Intern Med       Date:  2020-11-16       Impact factor: 1.271
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.